A Study to Evaluate the Efficacy and Safety of AST-001 in ASD Children

Astrogen

Status and phase: Active, not recruiting; Phase 3

Conditions: Autism Spectrum Disorder

Treatments: Drug: AST-001; Drug: Placebo of AST-001

Study type: Interventional

Funder types: Industry

Identifiers

NCT06333964

AST-001P_P301_ASD

Details and patient eligibility

About

1. Study purpose: To demonstrate the superiority of AST-001 compared to placebo in improving core symptoms of autism spectrum disorder (ASD) in children with ASD.
2. Background: ASD is a neurodevelopmental disorder characterized by deficits in social communication and social interaction as well as restricted, repetitive patterns of behavior, interests, or activities. There are no approved medicines to treat the core symptom of ASD. Although these drugs and other psychotropic medications are associated with side effects, the use of psychotropic drugs to treat associated psychiatric comorbidities is common. AST-001 is developed to treat the core symptom of ASD.
3. Design: Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 clinical trial followed by an Open-Label Extension Treatment Period

Enrollment: 169 patients

Sex: All

Ages: 2 to 7 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Those who meet the criteria of diagnostic and statistical manual of mental disorder (DSM)-5 during screening
• During screening period, individuals who are diagnosed with ASD through ADI-R assessment
• Subject with a CGI-S score of 4 or higher as a result of Clinical Global Impression(CGI) evaluation during baseline visit(visit 2)
• Subject or/and legally authorized representative voluntarily agreed to participate in this clinical trial and provided their informed consent by signing the written consent form
• In case of subjects who were receiving non-pharmacological therapy at the time of screening, the non-pharmacological therapy lasted at least 3 months prior to participation in screening and is expected to be sustainable during this clinical trial
• Subject whose legally authorized representative is able to participate in the provision of reliable information about the subject's condition, execute all scheduled site visits, oversee IP administration, fully understand and speak Korean, and conduct survey evaluation regarding the subject

Exclusion criteria

• At the time of screening, subject has the medical history, concomitant condition, or surgical history
• During the screening period, uncontrolled medical conditions,
• During the screening period, display of severe self-harm or injury to others that requires medical treatment, determined by investigator
• At the time of screening, weight over 60kg
• Inappropriate to participate in the trial determined by investigator

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

169 participants in 2 patient groups, including a placebo group

AST-001

Experimental group

Treatment:

Drug: AST-001

Placebo of AST-001

Placebo Comparator group

Treatment:

Drug: Placebo of AST-001